SHIM
ADMA icon

Stone House Investment Management’s ADMA Biologics ADMA Stock Holding History

Stone House Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104
Closed -$937 – 1341
2026
Q1 		$937 Sell
104
-35
-25% -$552 ﹤0.01% 709
2025
Q4 		$2.54K Buy
139
+130
+1,444% +$2.19K ﹤0.01% 530
2025
Q3 		$132 Buy
+9
New +$154 ﹤0.01% 711

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Stone House Investment Management's ADMA Position: Q2 2026 in Review

Stone House Investment Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 104 shares — an estimated $937 sold.

Stone House Investment Management first reported a position in ADMA in Q3 2025 and held it in 3 quarters. The position peaked at $2.54K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Stone House Investment Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Stone House Investment Management sold 104 ADMA Biologics shares in Q2 2026, an estimated $937.
  • Stone House Investment Management first reported a position in ADMA Biologics in Q3 2025 and held it in 3 quarters.
  • Stone House Investment Management's ADMA Biologics position peaked at $2.54K in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.